ERC Consolidator Grant · 2025
Epigenetic reactivation of oligodendroglial cells in Alzheimer’s disease
Alzheimer’s Disease (AD) is the most prominent neurodegenerative disease, representing a major public health issue worldwide. Unfortunately, the failure rate in clinical trials of AD drugs is one of the highest. One explanation could be our incompletely understanding of disease onset and progression. Notably the role of glial cells in AD has been overlooked until recently. EpiGlia aims at reactivating oligodendroglial cells to delay AD onset, by leveraging cell-specific and locus-targeted epigenetic tools. Indeed, the oligodendroglial cell lineage, by its myelinating role, plays a crucial role in the function and plasticity of the adult brain. But myelination declines in age-related…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.